TORONTO , June 12, 2014 /CNW/ - Concordia Healthcare Corp. (CXR.TO) (CHEHF), today announced that Mark Thompson , Chief Executive Officer, will present at the 2014 Bloom Burton & Co. Healthcare Investor Conference in Toronto, Ontario . Concordia's presentation will take place on Wednesday, June 18, 2014 , at 11:00 a.m. ET .
Bloom Burton's third annual healthcare investor conference features Canada's premier publicly-traded and venture-backed private companies. The event will attract Canadian, U.S. and European investors who are interested in the latest developments in Canadian healthcare companies.
Concordia is a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population. The Company's legacy pharmaceutical business consists of Donnatal®, an adjunctive therapy in the treatment of IBS and acute enterocolitis, an ADHD-treatment drug, Kapvay® (clonidine extended release tablets), Ulesfia® (benzyl alcohol) Lotion a Head Lice Treatment, and an Asthma-related medication, Orapred ODT® (prednisolone sodium phosphate orally disintegrating tablets). Concordia's Specialty Healthcare Distribution (SHD) division (Complete Medical Homecare) distributes medical supplies targeting diabetes and related conditions. Concordia's orphan division, Pinnacle, markets Photofrin® in the United States .
Concordia operates out of facilities in Oakville, Ontario , Bridgetown, Barbados , Lenexa, Kansas (near Kansas City, Missouri ), Bannockburn (near Chicago ), Illinois , and Charlottesville, Virginia .
SOURCE Concordia Healthcare Corp.
- Health Care Industry